All Clinical Trials

A listing of 23116 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Offer

Lose 20% of Body Weight With GLP-1's

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).

Get $50 off your first order using promo code: policy-lab-50

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

COVID-19 Vaccine Clinical Trial (Compensation Provided)

Recruiting

Healthy adults ages 50-64 may qualify. You may be eligible if you haven’t received a COVID-19 vaccine and haven’t had COVID-19 in the last 90 days.

Qualified participants may receive compensation for time and travel.

Conditions:

Healthy

Vaccine

COVID19

COVID-19

COVID-19 Vaccine

Learn More

Featured Trial

Type 2 Diabetes (T2DM) Clinical Study

Recruiting

A clinical study for people that suffer with Type 2 Diabetes (T2DM)

Conditions:

Type 2 Diabetes (T2DM)

Learn More

Featured Therapy

Unique Treatment for High Blood Pressure

Worried about high blood pressure? Think beyond typical high blood pressure treatments.

People who may be candidates for this procedure:

• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹

Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.

¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.

Conditions:

High Blood Pressure

High Blood Pressure (& [Essential Hypertension])

High Blood Pressure (Hypertension).

Hypertension

Essential Hypertension

Learn More

Systemic Lupus Erythematosus in Gullah Health

NCT00756769

Recruiting

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations. African Americans are at a disproportionately higher risk of developing SLE, develop SLE at an earlier age, and have increased morbidity and mortality compared with European Americans. Our central study hypothesis is that there are specific genetic factors that interact with environmental exposures... Read More

Gender:

ALL

Ages:

2 years and above

Trial Updated:

07/07/2025

Locations: Medical University of South Carolina, Charleston, South Carolina

Conditions: Systemic Lupus Erythematosus

Learn More ›

Childhood Cancer Survivor Study

NCT01120353

Recruiting

The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic mod... Read More

Gender:

ALL

Ages:

All

Trial Updated:

07/07/2025

Locations: University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama +30 locations

University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama

City of Hope National Medical Center, Duarte, California

Children's Hospital Los Angeles, Los Angeles, California

University of California-Los Angeles, Los Angeles, California

Children's Hospital of Orange County, Orange, California

University of California-San Francisco, San Francisco, California

Stanford University School of Medicine, Stanford, California

Children's Hospital Colorado, Aurora, Colorado

Children's National Medical Center, Washington, District of Columbia

Emory University/Children's Health Care of Atlanta, Atlanta, Georgia

Ana & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

University of Chicago, Chicago, Illinois

Indiana University/Riley Hospital for Children, Indianapolis, Indiana

Dana-Farber Cancer Institute, Boston, Massachusetts

University of Michigan/Mott Children's Hospital, Ann Arbor, Michigan

Children's Hospitals & Clinics of Minnesota, Minneapolis, Minnesota

University of Minnesota, Minneapolis, Minnesota

Mayo Clinic, Rochester, Minnesota

St. Louis Children's Hospital/The Washington University, Saint Louis, Missouri

Roswell Park Cancer Institute, Buffalo, New York

Memorial-Sloan Kettering Cancer Center, New York, New York

Nationwide Children's Hospital, Columbus, Ohio

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

St. Jude Children's Research Hospital, Memphis, Tennessee

University of Texas Southwestern Medical Center, Dallas, Texas

Cook Children's Medical Center, Fort Worth, Texas

M.D. Anderson Cancer Center, Houston, Texas

Texas Children's Hospital, Houston, Texas

Seattle Children's Hospital, Seattle, Washington

The Hospital for Sick Children, Toronto, Ontario

Conditions: Cancer

Learn More ›

Natural History Study of Children and Adults With Medullary Thyroid Cancer

NCT01660984

Recruiting

Background: - Medullary thyroid cancer (MTC) is a rare cancer of the thyroid gland. In children and adults, it is often part of a condition called Multiple Endocrine Neoplasia 2 (MEN2). MEN2 is usually caused by a genetic mutation, and it can cause a number of problems in addition to MTC. These problems include adrenal gland tumors, hormone changes, and problems with the bones and other organs. Not much is known about how MTC develops over time, especially in people with MEN2. Researchers want... Read More

Gender:

ALL

Ages:

4 months and above

Trial Updated:

07/07/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Medullary Thyroid Cancer

Learn More ›

Germ Cell Tumor and Testicular Tumor DNA Registry

NCT02099734

Recruiting

This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. This study will help us learn more about the prevention, diagnosis, treatment and outcome of these tumors. Studying relatives of patients and people unrelated to patients with GCT and other testicular tumors will help us understand why some people get these tum... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +7 locations

Conditions: Germ Cell Tumor, Testicular Tumor

Learn More ›

Pediatric Patients With Metabolic or Other Genetic Disorders

NCT02769949

Recruiting

Background: Some patients with unusual genetic conditions are referred to the National Institutes of Health (NIH). They may not be eligible to join current research studies. Testing such patients is a good way to improve the skills of research staff. The findings could lead to new processes and research. Objectives: To recruit a diverse group of pediatric subjects with genetic disorders. To give clinic staff hands-on experience working with these patients. Eligibility: Children any age with... Read More

Gender:

ALL

Ages:

Between 1 year and 99 years

Trial Updated:

07/07/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Genetic Disorder, Asperger Disorder, Autism Spectrum Disorder, Fragile X Syndrome, Developmental Delay

Learn More ›

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

NCT02974595

Recruiting

Background: Some diseases cause chronic inflammation with intermittent flares in the body. These are called autoinflammatory diseases. They can cause fevers, rashes, ulcers, and other problems. Researchers want to learn more about the causes and effects of these diseases. They hope this will improve how the disease is managed in the future. Objectives: To understand the underlying immune dysregulation To identify the genetic cause To translate our findings into novel treatments that improve patients disease outcomes Eligibility: Patients with known NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still's Disease, and with other yet undifferentiated autoinflammatory diseases. Unaffected relatives of participants with a known or undifferentiated autoinflammatory disease Healthy adult volunteers at least 18 years of age Design: Participants will be screened with blood sample and medical history. They may provide copies of their medical records. Enrolled participants will be evaluated at the NIH for 2-5 days. All participants will have a detailed medical history, physical exam, blood tests, and other evaluations depending on the extent of their autoinflammatory disease. Participants may also expect the following assessments: 1. Clinical tests that help assess organ damage and function such as hearing, vision, memory, and learning tests. 2. Imaging studies to characterize organ involvement of the inflammatory disease including: X-rays, CT scans, special MRIs, and bone scans. 3. Laboratory evaluations including clinical markers of disease activity, research samples for genetic studies, blood samples for cytokine/biomarker assessment, and gene expression profiling. 4. Questionnaires to assess disease activity and quality of life. 5. If indicated, other procedures may be administered that include: a lumbar puncture if CNS inflammation is suspected, a skin biopsy if skin inflammation is present, and/or gastrointestinal and pulmonary procedures if they are clinically indicated. Participants may return for a single follow-up visit or for long-term follow-up visits depending on their disease and willingness to return. Long-term follow-up may occur for up to 15 years on this protocol. Read Less

Gender:

ALL

Ages:

99 years and below

Trial Updated:

07/07/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: NOMID, DIRA, NLRC4-MAS, SAVI, CANDLE

Learn More ›

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NCT03093116

Recruiting

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More

Gender:

ALL

Ages:

12 years and above

Trial Updated:

07/07/2025

Locations: Local Institution - 2129, Duarte, California +164 locations

Local Institution - 2129, Duarte, California

Local Institution - 2120, Glendale, California

Local Institution - 2136, La Jolla, California

Local Institution - 2114, La Jolla, California

Local Institution - 2121, Long Beach, California

Local Institution - 2101, Orange, California

University of California Irvine Medical Center, Orange, California

Local Institution - 2126, Santa Rosa, California

Local Institution - 1003, Aurora, Colorado

Local Institution - 2103, Aurora, Colorado

Local Institution - 2106, Washington, District of Columbia

Local Institution - 2110, Washington, District of Columbia

Local Institution - 2128, Hollywood, Florida

Local Institution - 2113, Tampa, Florida

Local Institution - 2139, Athens, Georgia

Local Institution - 2134, Columbus, Georgia

Local Institution - 2125, Chicago, Illinois

Local Institution - 2142, Peoria, Illinois

Local Institution - 2116, New Orleans, Louisiana

Local Institution - 2133, Baltimore, Maryland

Local Institution - 2104, Boston, Massachusetts

Local Institution - 1004, Boston, Massachusetts

Local Institution - 2131, Boston, Massachusetts

Local Institution - 2105, Ann Arbor, Michigan

Local Institution - 2111, Detroit, Michigan

Local Institution - 2140, Detroit, Michigan

Local Institution - 2132, Saint Paul, Minnesota

Local Institution - 2147, Bolivar, Missouri

Local Institution - 2115, Saint Louis, Missouri

Local Institution - 2122, New Brunswick, New Jersey

Local Institution - 2117, New York, New York

Local Institution - 2102, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Local Institution - 2144, Goldsboro, North Carolina

Local Institution - 2112, Canton, Ohio

Local Institution - 2143, Cincinnati, Ohio

Local Institution - 2109, Cleveland, Ohio

Local Institution - 2123, Columbus, Ohio

Local Institution - 2119, Toledo, Ohio

Local Institution - 2108, Philadelphia, Pennsylvania

Local Institution - 2148, Memphis, Tennessee

Local Institution - 2130, Dallas, Texas

Local Institution - 2127, Houston, Texas

Local Institution - 2138, Houston, Texas

Local Institution - 2146, Kingwood, Texas

Local Institution - 2137, Fairfax, Virginia

Local Institution - 2107, Seattle, Washington

Local Institution - 2141, Tacoma, Washington

Local Institution - 2145, Appleton, Wisconsin

Local Institution - 6102, Camperdown, New South Wales

Local Institution - 6103, Adelaide, South Australia

Local Institution - 6101, Melbourne, Victoria

Local Institution - 3301, East Melbourne, Not set

Local Institution - 4802, Antwerp, Not set

Local Institution - 4801, Leuven, Not set

Local Institution - 2202, Edmonton, Alberta

Local Institution - 2205, Vancouver, British Columbia

Local Institution - 2201, Toronto, Ontario

Local Institution - 6503, Toronto, Ontario

Local Institution - 2203, Ontario, Not set

Local Institution - 2204, Ottawa, Not set

Local Institution - 6702, Beijing, Beijing

Beijing Cancer hospital, Beijing, Beijing

Daping Hospital, the Third Affiliated Hospital of Third Military Medical University /Cancer Center, Daping, Chongqing

Local Institution - 6719, Fuzhou, Fujian

The First Affiliated hospital of Xiamen University-oncology, Xiamen, Fujian

Guangdong Provincial People'S Hospital, Guangzhou, Guangdong

Local Institution - 6733, Guangzhou, Guangdong

Local Institution - 6505, Shenzhen, Guangdong

The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang

Local Institution - 6504, Shatin, Hong Kong

Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology/Cancer Center Department, Wuhan, Hubei

Local Institution - 6705, Changsha, Hunan

Hunan Cancer Hospital-thoracic oncology II, Changsha, Hunan

Local Institution - 6748, Nanjing, Jiangsu

XuZhou Central Hospital/Oncology Department, Xuzhou City, Jiangsu

Jilin Cancer Hospital/Medical Oncology Department, Changchun, Jilin

The first hospital of Jilin university-Oncology Department, Changchun, Jilin

Liaoning Cancer Hospital, Shenyang, Liaoning

Tangdu Hospital, Xi'an, Shan3xi

Shanxi Bethune Hospital, Taiyuan, Shanxi

Sichuan Cancer Hospital/Medical Oncology Department, Chengdu City, Sichuan

The First Hospital Affiliated To AMU - Southwest Hospital, Chongqing, Sichuan

Local Institution - 6725, Hangzhou, Zhejiang

Zhejiang Cancer Hospital-Oncology, Hangzhou, Zhejiang

The Third Xiangya Hospital of Central South University/Department of Respiratory and Critical Care Medicine, Changsha, Not set

West China Hospital Sichuan University/Lung cancer center, Chengdu, Not set

The First Affiliated Hospital - Zhejiang University School of Medicine, Hangzhou, Not set

Anhui Provincial Hospital, Hefei, Not set

Shanghai Chest Hospital, Shanghai, Not set

Weifang People's Hospital/Medical Oncology Department, Weifang City, Not set

Henan Cancer Hospital/The 1st pneumology department, Zhengzhou, Not set

Local Institution - 4901, Copenhagen, Not set

Local Institution - 4201, Marseille, Bouches-du-Rhône

Local Institution - 4207, Brest, Not set

Local Institution - 4204, Dijon Cedex, Not set

Local Institution - 4206, Grenoble Cedex 9, Not set

Centre Antoine-Lacassagne, Nice, Not set

Chu Poitiers, Poitiers, Not set

Local Institution - 4203, St Mande, Not set

Institute Gustave Roussy, Villejuif, Not set

Local Institution - 4704, Berlin, Not set

Local Institution - 4703, Dresden, Not set

Local Institution - 4702, Heidelberg, Not set

Local Institution - 4701, Koln, Not set

Local Institution - 6502, Hong Kong, Not set

Local Institution - 6501, Hong Kong, Not set

Local Institution - 5101, Budapest, Not set

Local Institution - 5103, Budapest, Not set

Local Institution - 4301, Milano, MI

Local Institution - 4306, Milano, Not set

Local Institution - 4307, Palermo, Not set

Local Institution - 4303, Pordenone, Not set

Local Institution - 4304, Ravenna, Not set

Local Institution - 4305, Reggio Emilia, Not set

Local Institution - 4308, Roma, Not set

Local Institution - 4302, Terni, Not set

Ehime University Hospital, Toon, Ehime

Hokkaido University Hospital, Sapporo-shi, Hokkaido

Kanagawa cancer center, Yokohama, Kanagawa

Osaka City General Hospital, Osaka-shi, Osaka

National Cancer Center Hospital., Chuo-ku, Tokyo

Tottori University Hospital, Yonago, Tottori

National Cancer Center Hospital East, Kashiwa, Not set

Nagoya University Hospital, Nagoya-shi, Not set

Osaka International Cancer institute, Osaka, Not set

Local Institution - 3003, Seoul, Gangnam-gu

Local Institution - 6308, Hwasun-eup, Hwasun-gun, Jeonnam

Yonsei University Health System, Seoul, Seodaemun-gu

Local Institution - 3002, Seoul, Seoul Teugbyeolsi

Local Institution - 6301, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 6303, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 6306, Cheongju-si, Not set

Seoul National University Hospital, Seoul, Not set

Local Institution - 6302, Seoul, Not set

Local Institution - 6307, Seoul, Not set

Local Institution - 6305, Seoul, Not set

Local Institution - 6304, Seoul, Not set

Local Institution - 4502, Amsterdam, Not set

Local Institution - 4501, Groningen, Not set

Ośrodek Badań Klinicznych Wczesnych Faz, Uniwersyteckie Centrum Kliniczne, Gdańsk, Not set

Local Institution - 4604, Lublin, Not set

Local Institution - 4605, Poznań, Not set

Local Institution - 4603, Szczecin, Not set

Local Institution - 4602, Warszawa, Not set

Local Institution - 6401, Singapore, Not set

Local Institution - 6402, Singapore, Not set

Local Institution - 4102, Barcelona, Not set

Local Institution - 4101, Barcelona, Not set

Local Institution - 4106, Madrid, Not set

Local Institution - 4104, Madrid, Not set

Local Institution - 4103, Madrid, Not set

Local Institution - 4105, Madrid, Not set

Clinica Universidad de Navarra, Pamplona, Not set

Instituto Valenciano de Oncología (IVO) - Unidad de Investigación Clínica FINCIVO, Valencia, Not set

Local Institution - 6201, Taiepi, Not set

Local Institution - 6203, Tainan, Not set

Local Institution - 6202, Taipei, Not set

Local Institution - 4401, London, Not set

Local Institution - 4402, London, Not set

Local Institution - 4404, London, Not set

Local Institution - 4403, Manchester, Not set

Local Institution - 4405, Sutton, Not set

Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors

Learn More ›

Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study

NCT03144206

Recruiting

A parallel-group randomized pilot trial at a single institution (Duke University) on the effect of postoperative hyperbaric oxygen therapy on wound healing in patients with soft tissue sarcoma undergoing surgical resection with neo-adjuvant radiation therapy.. Participants will be allocated to either the treatment group (HBOT) or control (standard of care) by computer-generated randomization, stratified by tumor size (≤10cm and \>10cm). An unequal randomization of 2:1 will be utilized to provide... Read More

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

07/07/2025

Locations: Duke University, Durham, North Carolina

Conditions: Sarcoma, Hyperbaric Oxygen Therapy

Learn More ›

A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

NCT03152318

Recruiting

This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: Johns Hopkins University Medical Center, Baltimore, Maryland +4 locations

Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme

Learn More ›

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT03331198

Recruiting

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +84 locations

University of Alabama at Birmingham, Birmingham, Alabama

University of Alabama Birmingham, Birmingham, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

City of Hope, Duarte, California

City Of Hope, Duarte, California

UC San Diego Moores Cancer Center, La Jolla, California

University Of California San Diego Moores Cancer Center, La Jolla, California

Local Institution - 0059, Los Angeles, California

University of California, Los Angeles, Los Angeles, California

Local Institution - 0010, San Francisco, California

University of California, San Francisco, San Francisco, California

Colorado Blood Cancer Institute, Denver, Colorado

Local Institution - 0110, Newark, Delaware

Georgetown University Medical Center, Washington, District of Columbia

Local Institution - 0085, Washington, District of Columbia

Mayo Clinic - Jacksonville, Jacksonville, Florida

Mayo Clinic, Jacksonville, Florida

Local Institution - 0104, Atlanta, Georgia

Local Institution - 0019, Atlanta, Georgia

The Blood and Marrow Transplant Group of Georgia (BMTGA), Atlanta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

Northwestern University, Chicago, Illinois

University of Chicago Medical Center, Chicago, Illinois

University Of Chicago Medical Center, Chicago, Illinois

Franciscan St. Francis Health - Indiana Blood and Marrow Transplantation (IBMT), Indianapolis, Indiana

Local Institution - 0107, Wichita, Kansas

Norton Healthcare - Norton Cancer Institute, Louisville, Kentucky

Local Institution - 0027, New Orleans, Louisiana

Local Institution - 0005, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Local Institution - 0015, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Local Institution - 0062, Detroit, Michigan

Local Institution - 0109, Detroit, Michigan

Mayo Clinic, Rochester, Minnesota

University of Nebraska Medical Center, Omaha, Nebraska

University Of Nebraska Medical Center, Omaha, Nebraska

Local Institution - 0001, Basking Ridge, New Jersey

Astera Cancer Care, Edison, New Jersey

John Theurer Cancer Center, Hackensack, New Jersey

Hackensack University Medical Center, Hackensack, New Jersey

Atlantic Health System / Morristown Medical Center, Morristown, New Jersey

Local Institution - 0077, New Brunswick, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Local Institution - 0035, New York, New York

Columbia University Medical Center, New York, New York

Local Institution - 0026, New York, New York

Weill Cornell Medical College, New York, New York

Local Institution - 0089, Stony Brook, New York

Duke University Medical Center, Durham, North Carolina

University Hospitals Seidman Cancer Center (Case Western), Cleveland, Ohio

University Hospitals Cleveland Medical Center, Cleveland, Ohio

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

University of Oklahoma Health Sciences Center (Stephenson Cancer Center), Oklahoma City, Oklahoma

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma

Local Institution - 0098, Eugene, Oregon

University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

Thomas Jefferson University - Clinical Research Institute, Philadelphia, Pennsylvania

Thomas Jefferson University, Philadelphia, Pennsylvania

Local Institution - 0029, Pittsburgh, Pennsylvania

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Baylor University Medical Center, Dallas, Texas

Local Institution - 0083, Dallas, Texas

University of Texas Southwestern Medical Center, Dallas, Texas

Local Institution - 0079, Dallas, Texas

The University of Texas - MD Anderson Cancer Center, Houston, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Local Institution - 0028, Salt Lake City, Utah

Local Institution - 0113, Charlottesville, Virginia

Local Institution - 0087, Richmond, Virginia

Virginia Commonwealth University, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

Local Institution - 0018, Seattle, Washington

Froedtert Hospital BMT Medical College of Wisconsin, Milwaukee, Wisconsin

Medical College of Wisconsin, Milwaukee, Wisconsin

Local Institution - 0112, Toronto, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic

Learn More ›

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

NCT03467516

Recruiting

This is a Phase 2 study in which the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with metastatic uveal melanoma will be evaluated. Metastatic uveal melanoma (UM) carries a poor prognosis with estimated survival of 4-6 months. There are no known effective systemic therapies. Metastatic UM is classified as an "orphan" disease and there are currently few clinical trial options for these patients. T... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

07/07/2025

Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Conditions: Uveal Neoplasms, Melanoma, Uveal

Learn More ›

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

NCT03801083

Recruiting

This is a Phase 2 study to evaluate the efficacy, using objective response rate, of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous Tumor Infiltrating Lymphocytes (TIL) and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic biliary tract cancer. These are low-incidence cancers carry a poor prognosis. Participants will include patients with biliary tract cancers (BTC), including cholangiocarcinoma (both intrahepatic and ext... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

07/07/2025

Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Conditions: Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Neoplasms

Learn More ›